Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate
Andrea Kokorovic(Dalhousie University), Neema Navai(The University of Texas MD Anderson Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Kate J. Krause(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center), Mary E. Westerman(The University of Texas MD Anderson Cancer Center), Nathan A. Brooks(Eli Lilly (United States)), Mike Hernández(The University of Texas MD Anderson Cancer Center)
Cited by 10
Related Papers
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|The Lancet Oncology|2016|1.1k
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297